Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and OPKO Health Inc. (NASDAQ:OPK) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.
Earnings and Valuation
Demonstrates Brainstorm Cell Therapeutics Inc. and OPKO Health Inc. earnings per share (EPS), gross revenue and valuation.
Profitability
Table 2 shows us the return on equity, net margins and return on assets of both companies.
Risk & Volatility
Brainstorm Cell Therapeutics Inc.s current beta is 1.19 and it happens to be 19.00% more volatile than S&P 500. OPKO Health Inc.s 2.13 beta is the reason why it is 113.00% more volatile than S&P 500.
Liquidity
The Current Ratio and a Quick Ratio of Brainstorm Cell Therapeutics Inc. are 1 and 1. Competitively, OPKO Health Inc. has 1.1 and 1 for Current and Quick Ratio. OPKO Health Inc.s better ability to pay short and long-term obligations than Brainstorm Cell Therapeutics Inc.
Analyst Ratings
Brainstorm Cell Therapeutics Inc. and OPKO Health Inc. Ratings and Recommendations are available on the next table.
The upside potential is 147.25% for Brainstorm Cell Therapeutics Inc. with consensus target price of $9.
Insider & Institutional Ownership
Brainstorm Cell Therapeutics Inc. and OPKO Health Inc. has shares held by institutional investors as follows: 11.4% and 26.4%. Brainstorm Cell Therapeutics Inc.s share held by insiders are 0.6%. Competitively, insiders own roughly 5.5% of OPKO Health Inc.s shares.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
For the past year Brainstorm Cell Therapeutics Inc. has 12.96% stronger performance while OPKO Health Inc. has -29.9% weaker performance.
Summary
OPKO Health Inc. beats Brainstorm Cell Therapeutics Inc. on 7 of the 11 factors.
Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companys Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companys pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
See the rest here:
Brainstorm Cell Therapeutics Inc. (BCLI) and OPKO Health Inc. (NASDAQ:OPK) Comparison side by side - MS Wkly